Date
- Monday, 7 September 2015, All day
Location
- European Medicines Agency, Amsterdam, the Netherlands
On 7 September 2015 the European Medicines Agency (EMA) organised a face-to-face meeting to follow-up the meeting which took place on 6 July. The aim of this meeting was to further consult with stakeholders on the two sets of guidance under development, on the identification and redaction of commercially confidential information in the clinical reports submitted to the EMA for publication, and on the anonymisation of the clinical reports, in the context of the policy. EMA also presented new technical guidance on the procedural aspects related to the submission of the clinical reports, for example practical matters of how material should be sent to EMA, as well as the workflow of the redaction consultation process and the overall process leading to publication.